Monitoring the macrophage response towards biomaterial implants using label-free imaging

Lu, Chuan-en; Levey, Ruth E.; Ghersi, Giulio; Schueller, Nathan; Liebscher, Simone; Layland, Shannon L.; Schenke-Layland, Katja; Duffy, Garry P.; Marzi, Julia

doi:10.1016/j.mtbio.2023.100696

Cited by 3 publications

(2 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Macrophages are considered a good indicator for the biocompatibility evaluation of implants ( Lužajić Božinovski et al, 2022 ; Lu et al, 2023 ). In which the M1 macrophage generates pro-inflammatory such as IL-6 and TNF- α, while the M2 macrophages function as tissue remodeling and regeneration ( Pérez and Rius-Pérez, 2022 ; Yu et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Assessment of inflammatory suppression and fibroblast infiltration in tissue remodelling by supercritical CO2 acellular dermal matrix (scADM) utilizing Sprague Dawley models

Ngan Giang,

Le,

Ngoc Chien

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Human skin-derived ECM aids cell functions but can trigger immune reactions; therefore it is addressed through decellularization. Acellular dermal matrices (ADMs), known for their regenerative properties, are used in tissue and organ regeneration. ADMs now play a key role in plastic and reconstructive surgery, enhancing aesthetics and reducing capsular contracture risk. Innovative decellularization with supercritical carbon dioxide preserves ECM quality for clinical use. The study investigated the cytotoxicity, biocompatibility, and anti-inflammatory properties of supercritical CO2 acellular dermal matrix (scADM) in vivo based on Sprague Dawley rat models. Initial experiments in vitro with fibroblast cells confirmed the non-toxic nature of scADM and demonstrated cell infiltration into scADMs after incubation. Subsequent tests in vitro revealed the ability of scADM to suppress inflammation induced by lipopolysaccharides (LPS) presenting by the reduction of pro-inflammatory cytokines TNF-α, IL-6, IL-1β, and MCP-1. In the in vivo model, histological assessment of implanted scADMs in 6 months revealed a decrease in inflammatory cells, confirmed further by the biomarkers of inflammation in immunofluorescence staining. Besides, an increase in fibroblast infiltration and collagen formation was observed in histological staining, which was supported by various biomarkers of fibroblasts. Moreover, the study demonstrated vascularization and macrophage polarization, depicting increased endothelial cell formation. Alteration of matrix metalloproteinases (MMPs) was analyzed by RT-PCR, indicating the reduction of MMP2, MMP3, and MMP9 levels over time. Simultaneously, an increase in collagen deposition of collagen I and collagen III was observed, verified in immunofluorescent staining, RT-PCR, and western blotting. Overall, the findings suggested that scADMs offer significant benefits in improving outcomes in implant-based procedures as well as soft tissue substitution.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of inflammatory suppression and fibroblast infiltration in tissue remodelling by supercritical CO2 acellular dermal matrix (scADM) utilizing Sprague Dawley models

Ngan Giang,

Le,

Ngoc Chien

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Macrophages are considered a good indicator for the biocompatibility evaluation of implants (Lužajić Božinovski et al, 2022;Lu et al, 2023). In which the M1 macrophage generates proinflammatory such as IL-6 and TNF-α, while the M2 macrophages function as tissue remodeling and regeneration (Pérez and Rius-Pérez, 2022;Yu et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

DataSheet1.ZIP

View full text Add to dashboard Cite

Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer

Xu,

Zhou,

Yang

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Pazopanib (PAZ), an oral multi-tyrosine kinase inhibitor, demonstrates promising cytostatic activities against various human cancers. However, its clinical utility is limited by substantial side effects and therapeutic resistance. We developed a nanoplatform capable of delivering PAZ for enhanced anti-breast cancer therapy. Nanometer-sized PAZ@Fe-MOF, compared to free PAZ, demonstrated increased anti-tumor therapeutic activities in both syngeneic murine 4T1 and xenograft human MDA-MB-231 breast cancer models. High-throughput single-cell RNA sequencing (scRNAseq) revealed that PAZ@Fe-MOF significantly reduced pro-tumorigenic M2-like macrophage populations at tumor sites and suppressed M2-type signaling pathways, such as ATF6-TGFBR1-SMAD3, as well as chemokines including CCL17, CCL22, and CCL24. PAZ@Fe-MOF reprogramed the inhibitory immune microenvironment and curbed tumorigenicity by blocking the polarization of M2 phenotype macrophages. This platform offers a promising and new strategy for improving the cytotoxicity of PAZ against breast cancers. It provides a method to evaluate the immunological response of tumor cells to PAZ-mediated treatment.

show abstract

Monitoring the macrophage response towards biomaterial implants using label-free imaging

Cited by 3 publications

References 76 publications

Assessment of inflammatory suppression and fibroblast infiltration in tissue remodelling by supercritical CO2 acellular dermal matrix (scADM) utilizing Sprague Dawley models

Assessment of inflammatory suppression and fibroblast infiltration in tissue remodelling by supercritical CO2 acellular dermal matrix (scADM) utilizing Sprague Dawley models

DataSheet1.ZIP

Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer

Contact Info

Product

Resources

About